NEW YORK, August 24, 2026, 06:20 EDT — Shares in Cardinal Health declined 4.5% as $60 million worth of insider sales led to scrutiny over whether the company’s buyback program can continue to support the stock price.
- Cardinal Health was quoted at $219.21 ahead of the open on Monday, a decline of 4.49% compared with Friday.
- Senior executives reported stock sales totaling close to $60 million following the August 11 record high.
- The sales represent under 1% of Cardinal Health’s $6.4 billion buyback authorization.
- Analysts stay upbeat, with the average price target at $270.94 based on 18 estimates.
Shares of Cardinal Health, Inc. NYSE:CAH dropped 4.5% in premarket trading on Monday, deepening a recent pullback after reaching a record high following earnings. The stock was last indicated at $219.21, down from a close of $229.51 on Friday.
The new pressure comes after executive stock sales totaling nearly $60 million. Chief Executive Jason Hollar was responsible for roughly half of that sum. The sales occurred a week after positive guidance pushed shares to an intraday peak of $258.30.
The comparison in scale is significant for investors. The insider stock sales represent roughly 0.9% of Cardinal Health’s $6.4 billion buyback authorization. However, the timing comes after a rapid rally, putting confidence to the test.
| Market marker | Price | Change |
|---|---|---|
| August 11 intraday high | $258.30 | — |
| August 11 end of day | $240.26 | +1.30% on the session |
| August 21 end of day | $229.51 | -4.47% versus August 11 close |
| August 24 before market open | $219.21 | -4.49% since Friday; -15.1% from intraday peak |
On August 18 and 19, Hollar disposed of 124,529 shares for approximately $29.4 million, with sale prices spanning $233.22 to $237.88. Premarket levels were below these prices.
| Executive | Role | Reported sale value |
|---|---|---|
| Jason Hollar | Chief executive | $29.4 million |
| Aaron Alt | Chief financial officer | $9.9 million |
| Stephen Mason | GMPD division CEO | $8.3 million |
| Jessica Mayer | Chief legal and compliance officer | About $7.0 million |
| Michelle Greene | Chief information officer | $2.7 million |
| Deborah Weitzman | PSS division CEO | $1.7 million |
| Total | Six listed executives | About $59.0 million |
The sales stand in contrast to Cardinal Health’s capital-return strategy. The company’s management anticipates repurchasing roughly $1 billion in fiscal 2027. In addition, the board increased its authorization by $5 billion, raising the total available capacity to $6.4 billion.
| Capital action | Value | Scale at $219.21 |
|---|---|---|
| Six top executives sold shares | Roughly $59 million | 0.9% of the authorized amount |
| Repurchases planned for FY2027 | Roughly $1 billion | Approximately 4.6 million shares |
| Overall buyback authorization | $6.4 billion | Roughly 29.2 million shares |
| Forecast diluted share total | Roughly 233 million | Authorization covers 12.5% |
Business momentum stayed robust. Revenue for the fiscal fourth quarter increased by 6% to $63.7 billion. Adjusted earnings were $2.91 per share, factoring in a 31-cent per share benefit from a tariff refund.
After stripping out that benefit, Cardinal Health reported adjusted earnings of $2.60 per share. The company projected adjusted earnings for fiscal 2027 in the range of $12.40 to $12.60 per share, representing an increase of 13% to 15%.
“Fiscal 2026 was a remarkable year for Cardinal Health,” Hollar stated alongside the results. He noted that each of the five operating segments achieved double-digit profit increases prior to tariff recoveries.
| Metric | Q4/FY2026 result | FY2027 guide |
|---|---|---|
| Quarterly revenue | $63.7 billion, up 6% | — |
| Adjusted EPS | $2.91 reported; $2.60 without tariff refund | $12.40-$12.60 |
| Adjusted free cash flow | $5.0 billion in FY2026 | $3.5-$4.0 billion |
| Pharma revenue growth | 6% rise in Q4 | 3% to 5% growth |
| Other-segment revenue growth | 7% increase in Q4 | 11% to 13% higher |
Wall Street has not responded to the insider sales with widespread downgrades. Eighteen analysts maintain a Buy consensus. The average price target they set is $270.94, roughly 24% higher than Monday’s premarket indication.
| Analyst | Firm | Rating | Target | Date |
|---|---|---|---|---|
| Glen Santangelo | Barclays | Buy | $275 | Aug. 19 |
| Ryan Halsted | RBC Capital | Buy | $276 | Aug. 19 |
| Lisa Gill | J.P. Morgan | Hold | $260 | Aug. 17 |
| George Hill | Deutsche Bank | Hold | $261 | Aug. 13 |
| Steven Valiquette | Mizuho | Buy | $250 | Aug. 13 |
The stock is currently trading beneath all published targets. This difference leaves the debate unresolved. Cardinal Health’s distribution model yields slim margins, meaning minor execution changes can significantly impact profit.
Risks: Insider stock sales can indicate actions like diversification or tax-related strategies, not necessarily sentiment about the company’s outlook. Buyback approvals might not lead to actual share repurchases. Earnings performance could also be impacted by tariffs, integrating acquisitions, and specialty drug sales volumes.
Investors are advised to monitor regular-session volumes on Monday and focus on the $219-$220 range. The upcoming indication to watch for is if buybacks offset supply. Management’s ability to deliver fiscal 2027 cash flow will carry greater importance.
